Hoffmann-La Roche
Stories
-
Hoffmann-La Roche posts results of Phase 3 obinutuzumab trial in childhood nephrotic syndrome
The study, completed in September 2025, enrolled 85 participants aged 2-25 years and compared obinutuzumab with mycophenolate mofetil. Results were first posted on ClinicalTrials.gov on October 14, 2026.
-
Hoffmann-La Roche posts results of Phase 3 IMpower030 atezolizumab trial in resectable NSCLC
Results for the IMpower030 study were first posted on ClinicalTrials.gov on October 9, 2026. The Phase 3 trial enrolled 453 participants and completed primary data collection on October 1, 2025.
-
Hoffmann-La Roche posts results of Phase 3 alectinib rollover study
Results for the study were first posted on ClinicalTrials.gov on October 9, 2026. The completed Phase 3 rollover study enrolled 50 participants and compared alectinib with crizotinib in patients with ALK- or RET-positive cancer.